Skip to main content

View full-text article in PMC

. 2018 Jan 18;11(3):210–220. doi: 10.1007/s12265-018-9789-x

Table 2.

Median serum MMP-9 concentrations in the recovery phase relative to the acute phase

					MMP-9 (ng/ml)
					Median (IQR)	p value
				N		Compared to controls^a	Compared to acute phase^b	Compared to “no endpoint”^c
Controls				326	150.2 (189.4)
Cases	Acute phase	ACS		343	343.5 (298.7)	< 0.001	–	–
			UAP	108	302.4 (278.4)	< 0.001	–	–
			AMI	235	375.0 (330.4)	< 0.001	–	–
		MACE in the follow-up	No endpoint	193	322.2 (318.2)	< 0.001	–	–
			Non-fatal	89	327.6 (234.8)	0.011	–	< 0.001
			Fatal	61	419.3 (266.5)	< 0.001	–	< 0.001
	Recovery phase	ACS		157	174.6 (225.3)	NS	< 0.001	–
			UAP	56	178.2 (255.4)	NS	0.013	–
			AMI	101	172.9 (184.9)	NS	< 0.001	–
		MACE in the follow-up	No endpoint	94	182.4 (226.6)	NS	< 0.001	–
			Non-fatal	49	167.6 (214.0)	NS	< 0.001	NS
			Fatal	14	138.4 (295.9)	NS	0.003	NS

The statistically significant p values are in italics

NS not significant

^aMann-Whitney test

^bWilcoxon signed-rank test